Aura Biosciences (NASDAQ:AURA) Announces Quarterly Earnings Results

Aura Biosciences (NASDAQ:AURA – Get Rating) posted its earnings results on Wednesday. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.06, Yahoo Finance reports.

Aura Biosciences Price Performance

Shares of AURA opened at $10.21 on Friday. Aura Biosciences has a one year low of $9.43 and a one year high of $24.83. The stock has a 50-day moving average price of $10.55 and a 200 day moving average price of $12.30.

Analysts Set New Price Targets

Separately, JMP Securities dropped their price target on shares of Aura Biosciences from $30.00 to $25.00 and set an “outperform” rating on the stock in a research note on Thursday.

Insiders Place Their Bets

In other Aura Biosciences news, Director David Michael Johnson bought 4,000 shares of the business’s stock in a transaction on Wednesday, December 28th. The shares were bought at an average cost of $9.75 per share, with a total value of $39,000.00. Following the transaction, the director now directly owns 17,000 shares in the company, valued at approximately $165,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 5.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in AURA. BNP Paribas Arbitrage SNC bought a new position in shares of Aura Biosciences during the third quarter worth about $105,000. American International Group Inc. raised its stake in Aura Biosciences by 208.3% during the second quarter. American International Group Inc. now owns 8,577 shares of the company’s stock valued at $122,000 after buying an additional 5,795 shares in the last quarter. Renaissance Technologies LLC bought a new position in Aura Biosciences during the 4th quarter worth approximately $138,000. JPMorgan Chase & Co. grew its position in shares of Aura Biosciences by 272.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 9,798 shares of the company’s stock worth $139,000 after acquiring an additional 7,170 shares in the last quarter. Finally, Captrust Financial Advisors bought a new stake in shares of Aura Biosciences in the 2nd quarter valued at approximately $190,000. 55.63% of the stock is owned by institutional investors and hedge funds.

About Aura Biosciences

(Get Rating)

Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.